2011—2017年中国心肌梗死治疗质量的趋势与变异

doi:10.3969/j.issn.1006-5253.2021.02.001

Abstract
Figure/Table
References (0)
Related Citation (0)

Download: PDF (873 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To analyze the trend of utilization rate of treatment quality evaluation index for ST-segment elevation myocardial infarction (STEMI) from 2011 to 2017; to calculate the comprehensive treatment quality score of acute myocardial infarction to obtain the variation trend and variation of the comprehensive quality, and to provide evidence for improving the quality of STEMI treatment. Methods Twelve STEMI treatment quality evaluation indicators which were recommended by I kind in STEMI treatment guidelines were selected, and data of STEMI patients were extracted from the singledisease surveillance system to calculate the utilization rate of the STEMI treatment evaluation indicator. The denominator weighting method was used to obtain the comprehensive score and variation of treatment quality, and the trend test was conducted. Results Compared with 2011, among the 12 treatment quality indicators, the utilization rate of PCI within 90 min of hospital arrival increased the most, and the use rate of beta blockers immediately after hospital arrival decreased the most, showing a statistically significant trend test. Between 2011 and 2017, the comprehensive score of hospitals did not change obviously with time, but the interquartile interval increased with time. Conclusion The utilization rate of most of the treatment quality indexes of STEMI in China has been significantly improved; the trend of hospital comprehensive score was stable, but the variation between hospitals was enlarged.

Key words： acute ST-segment elevation myocardial infarction treatment quality index composite score trend and variation

Received: 22 September 2020

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	Li Jingkun
	Wang Xinyu
	Li Xi
	Wang Chao
	Liu Meina

Cite this article:

Li Jingkun,Wang Xinyu,Li Xi, et al. Trends and variations of myocardial infarction treatment quality in China from 2011 to 2017[J]. journal1, 2021, 28(2): 97-100.

URL:

http://manu58.magtech.com.cn/Jwk_zgyytj/EN/10.3969/j.issn.1006-5253.2021.02.001 OR http://manu58.magtech.com.cn/Jwk_zgyytj/EN/Y2021/V28/I2/97

［1］GBD 2016 HEALTHCARE ACCESS AND QUALITY COLLABORATORS. Measuring performance on the Healthcare Access and Quality Index for 195 countries and territories and selected subnational locations: A systematic analysis from the Global Burden of Disease Study 2016［J］. Lancet, 2018, 391(10136):2236-2271.
［2］MENG Q, XU L, ZHANG Y G, et al. Trends in access to health services and financial protection in China between 2003 and 2011: A cross-sectional study［J］. Lancet, 2012, 379(9818):805-814.
［3］LIU Y L, RAO K Q, WU J, et al. China′s health system performance［J］. Lancet, 2008, 372(9653):1914-1923.
［4］BLUMENTHAL D. Quality of care: What is it?［J］. American Journal of Ophthalmology, 1996, 122(3):99-101.
［5］World Health Organization. What is quality of care and why is it important? ［EB/OL］.［20200922］． https://www.who.int/maternal_child_adolescent/topics/quality-ofcare/definition/en/.
［6］李晓．Z医院急性心肌梗死诊疗过程质量控制的评价［D］．北京：北京中医药大学，2014．
［7］孙昕，顾建钧，贺晓燕，等．综合医院急性心肌梗死住院诊疗的过程质量分析［J］．中国医院管理，2014，34(10)：38-40． 
［8］中国医院协会．单病种质量管理手册:2.0版［M］．北京：科学技术文献出版社，2010．
［9］续红梅，刘茁，何敬堂，等．急性心肌梗死医疗质量改进效果分析［J］．中国病案，2013，14(9)：10-12．
［10］胡宪清，傅慎文，唐彪，等．高龄急性心肌梗死患者直接PCI疗效及安全性研究［J］．中华急诊医学杂志，2015，24(3)：277-280．
［11］ANTMAN E M, WIVIOTT S D, MURPHY S A, et al. Early and late benefits of prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention: A TRITON-TIMI 38 (TRial to assess improvement in therapeutic outcomes by optimizing platelet Inhibition with prasugrel-thrombolysis in myocardial infarction) analysis［J］. J Am Coll Cardiol, 2008, 51(21):2028-2033.
［12］ZHANG L H, LI J, LI X, et al. National assessment of statin therapy in patients hospitalized with acute myocardial infarction: Insight from China PEACE-retrospective AMI study, 2001, 2006, 2011［J］. PLoS One, 2016, 11(4):e0150806.
［13］张丽华，张海波，白雪珂，等．中国中西部城市医院急性心肌梗死住院患者2001、2006、2011年β受体阻滞剂早期使用变化趋势［J］．中国医药导报，2017，14(33)：69-73．
［14］ZHANG L H, DESAI N R, LI J, et al. National quality assessment of early clopidogrel therapy in Chinese patients with acute myocardial infarction (AMI) in 2006 and 2011: Insights from the China patient-centered evaluative assessment of cardiac events (PEACE)–retrospective AMI study［J］. J Am Heart Assoc, 2015, 4(7):e001906.
［15］霍西茜，张丽华，胡爽，等．2001～2011年中国中西部城市急性心肌梗死患者住院期间他汀应用情况及影响因素：China PEACE回顾性急性心肌梗死研究［J］．中国循环杂志，2017，32(z1)：77．
［16］杜方冬，孙振球，饶克勤．我国医院信息化发展水平的评价［J］．中国卫生统计，2010，27(1)：35-39．